- Company
- ↑Sales of local subsidiaries in Japan & Southeast Asia
- by Kim, Jin-Gu Mar 24, 2021 07:28am
- While the earnings of subsidiaries in China and North America, which were relatively affected by COVID-19, decreased significantly, the performance of local subsidiaries in Japan and Southeast Asia increased relatively. ◆↓20% sales of Beijing Hanmi / ↓13%, Ilyang / ↓12%, China According to the Financial Supervisory Service on th
- Company
- Pneumococcal vaccine Prevenar 13 lowers COVID-19 risk
- by Eo, Yun-Ho Mar 24, 2021 05:46am
- A study found a pneumococcal vaccine Prevenar 13 could lower the risk related to COVID-19. The Kaiser Permanente Southern California (KPSC) has recently presented the study result of the effect of Prevenar 13 (PCV13) on elderly patients’ COVID-19 infection progress. The study was published in the Journal of Infectious Diseases. The s
- Product
- Korean-made new drug Rolontis readies for FN drug market
- by Moon, sung-ho Mar 24, 2021 05:45am
- Hanmi Pharmaceutical is readying for the febrile neutropenia (FN) treatment market for its first bio new drug Rolontis (eflapegrastim), as it finally received the South Korean health authority’s market authorization. This could be an opportunity for the South Korean company to take over the domestic drug market, currently led by global phar
- Company
- Tagrisso expands benefits as a first-line treatment
- by Mar 24, 2021 05:45am
- Tagrisso, a targeted treatment for EGFR mutant non-small cell lung cancer, is not receiving benefits from the first-line treatment in Korea. The medical staff emphasized the need for Tagrisso's benefit. On the 19th, AstraZeneca Korea held an online press conference to commemorate the 5th anniversary of Tagrisso's postoperative adjuvant ther
- Policy
- CMOs tense up for a full day MFDS investigation
- by Lee, Tak-Sun Mar 23, 2021 06:24am
- Set off by the Binex incident, South Korea’s Ministry of Food and Drug Safety (MFDS) has started a full investigation on pharmaceutical contract manufacturing organizations (CMOs). Although it was a day-long investigation, the companies noted it was pressuring. According to the relevant industry sources on Mar. 22, two to three regional
- Company
- Domestic approval of Ajovy is imminent
- by Eo, Yun-Ho Mar 23, 2021 06:24am
- The second anti-CGRP mechanism following Emgality is expected to be approved in Korea. According to related industries, Teva Handok is in discussions for domestic approval of Ajovy(Fremanezumab), a migraine treatment targeting Calcitonin gene-related peptide (CGRP). Approval is possible within the first half of the year. The effectiven
- Policy
- New benefits for Epidiolex will be established from April
- by Lee, Jeong-Hwan Mar 23, 2021 06:23am
- New standard for Epidiolex (a drug for refractory childhood epilepsy) will be established. Democratic Party of Korea Rep. Nam In-soon and others strongly pointed out the validity of health insurance benefits at last year's national audit. Epidiolex costs about &8361;1.64 million per bottle, and up to &8361;40 million per year. On the 17
- Policy
- “Regular COVID-19 vaccination like flu vaccination"
- by Kim, Jung-Ju Mar 23, 2021 06:23am
- The South Korean health authority says the COVID-19 vaccination could be periodically provided in the future, similar to an influenza vaccination, due to the pandemic still spreading strong around the world. It also means the health authority would have to successfully develop an mRNA vaccine platform, in which the government plans to soo
- Company
- Who’ll be the 2nd Korean-made COVID-19 drug?
- by Kim, Jin-Gu Mar 23, 2021 06:23am
- Chong Kun Dang’s candidate COVID-19 treatment Nafabeltan has failed to get the South Korean health authority’s conditional approval. As the Ministry of Food and Drug Safety (MFDS) shut the first door of conditional approval to highly anticipated candidate Nafabeltan, the public is now curious of who would be the next second South Kore
- Policy
- The HIRA's reimbursed standards for chemotherapy are changed
- by Lee, Hye-Kyung Mar 23, 2021 06:23am
- The HIRA has changed the chemotherapy benefit standard, four criteria are changed and three criteria are deleted in relation to pancreatic cancer chemotherapy. Changes are made in a total of 25 criteria. The HIRA recently prepared an amendment to 'Details on the Standards and Methods of Applying Medical Care Benefits to Drugs Prescribed and A
